Overview

A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC

Status:
NOT_YET_RECRUITING

Trial end date:
2032-12-01

Target enrollment:

Participant gender:

Summary

This study is a randomized, controlled, open-label, multicenter Phase III clinical trial designed to compare the efficacy and safety of SHR-A2009 combined with aumolertinib versus aumolertinib monotherapy in treatment-nave subjects with EGFR-mutated, locally advanced or metastatic non-small cell lung cancer.

Phase:

PHASE3

Details

Lead Sponsor:

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Treatments:

aumolertinib